This is an example of collaboration, in this case between BIOLAN HEALTH and the QUIRÓNSALUD BIZKAIA HOSPITAL within the framework of the OSASUNBERRI initiative, which promotes the incorporation of 0 kilometer innovation into the Basque health system. Lactose intolerance affects 20% of our population. The new test, developed in collaboration with VENTER PHARMA, allows early...

BIOLAN HEALTH has been marketing its antigen tests for the detection of COVID for a year now, and since this week it has been able to market its self-testing antigen tests in pharmacies. Until now, BIOLAN HEALTH has only had the opportunity to market the tests for professional use to private companies or social-health institutions,...

At the Basque Health Cluster Assembly held on 9 June, the renewal of the Board of Directors was approved, whose president will now be Asier Albizu, CEO of Biolan Health, replacing Mikel Álvarez, president of Mondragon Unibertsitatea. The new management team will also be made up of: Julio Font, from Histocell, who will remain as...

Last Wednesday, 18 May, the first in-person edition of the Digital Transformation Forum entitled “Technology with an impact on health” was held, bringing together more than fifty companies and professionals to present some of the most innovative applications in the health sector in the Basque Country. BIOLAN HEALTH was present at the event held in...

OSASUNBERRI, an inter-regional collaborative initiative for innovation and investment in the Km 0 health industry and in the health care system, was presented in Bilbao on 4 October. Its aim is to join forces, create synergies and strengthen this sector in order to achieve efficient, comprehensive and sustainable management of current needs, as well as...

The recent expansion of SARS-COV-2 vaccines is generating an important debate about the immunity they generate against the virus, and knowing whether vaccines are effective is obviously of great concern to the population. The way to corroborate whether these vaccines have the desired effect by provoking the expected immune response is to check whether antibodies...

This collaborative action is part of a broader agreement reached between CIC bioGUNE and BIOLAN in areas aimed at disease diagnosis and other health applications. CIC bioGUNE -a member of the Basque Research & Technology Alliance, BRTA- and BIOLAN have signed a collaboration agreement to exchange the knowledge necessary for the development, manufacture and commercialisation...

The Basque SME located in Zamudio has invested heavily to equip itself with the equipment that will allow it to scale up the newly developed product.  Since January, BIOLAN has had a new product developed and validated with excellent results in terms of sensitivity (96%) and specificity (93%) and with all the necessary requirements for...